Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
about
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialDistinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung CancerReduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13.Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications.The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis.Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells.
P2860
Q26769884-A1196CF2-B3A9-48D6-9995-3C1A4800AF80Q28387027-F90D22A3-2162-476A-8461-38B5347D0175Q33671632-DAB04017-3893-43F4-8D6B-F917E9BE9A3BQ37432540-0CAF67C5-A68B-4D3D-B0F7-6675D9DF3913Q41472736-252A0A1F-77E0-4972-8B02-62F39DCAC7D9Q47566249-D5F99A5A-D710-43E7-99E6-0DF24D6EFD7BQ47994454-59631C19-164B-456C-9A6F-8A964BC08529Q48248991-CC34CBC7-9742-4BA7-8947-E13A2B4BC3A5Q50192132-A5AFE402-6E3D-41EC-92DF-D9A2F78F9A2CQ52653002-9555F317-AA39-415C-B683-FFE46149F5F0Q54977989-0B49CDA8-FD23-4DAD-BE9B-176C7B0D1D92
P2860
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tyrosine kinase inhibitors for ...... cent advances in therapeutics.
@en
type
label
Tyrosine kinase inhibitors for ...... cent advances in therapeutics.
@en
prefLabel
Tyrosine kinase inhibitors for ...... cent advances in therapeutics.
@en
P2860
P356
P1476
Tyrosine kinase inhibitors for ...... ecent advances in therapeutics
@en
P2093
Clement Chung
P2860
P304
P356
10.1177/1078155215577810
P577
2015-04-08T00:00:00Z